290 related articles for article (PubMed ID: 17450401)
1. Emergence of HIV-1 drug resistance during antiretroviral treatment.
Rong L; Feng Z; Perelson AS
Bull Math Biol; 2007 Aug; 69(6):2027-60. PubMed ID: 17450401
[TBL] [Abstract][Full Text] [Related]
2. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
[TBL] [Abstract][Full Text] [Related]
3. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
[TBL] [Abstract][Full Text] [Related]
4. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A
Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168
[TBL] [Abstract][Full Text] [Related]
5. The effects of antiretroviral dose modification on the re-emergence of HIV-1 wild-type strains.
Jenwitheesuk E; Auswinporn S; Vibhagool A; Chantratita W
Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):99-101. PubMed ID: 12118469
[TBL] [Abstract][Full Text] [Related]
6. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
[TBL] [Abstract][Full Text] [Related]
7. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
8. Transmission of HIV-1 drug resistance.
Tang JW; Pillay D
J Clin Virol; 2004 May; 30(1):1-10. PubMed ID: 15072747
[TBL] [Abstract][Full Text] [Related]
9. Dynamic treatment model to examine the association between phenotypic drug resistance and duration of HIV viral suppression.
Snedecor SJ
Bull Math Biol; 2005 Nov; 67(6):1315-32. PubMed ID: 16005505
[TBL] [Abstract][Full Text] [Related]
10. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads.
Wein LM; D'Amato RM; Perelson AS
J Theor Biol; 1998 May; 192(1):81-98. PubMed ID: 9628841
[TBL] [Abstract][Full Text] [Related]
11. Genotypic resistance tests for the management of the patient failing highly active antiretroviral therapy: the resistance pattern in different biological compartments.
Liuzzi G
Scand J Infect Dis Suppl; 2003; 106():90-3. PubMed ID: 15000595
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects.
Smith RJ; Wahl LM
Bull Math Biol; 2005 Jul; 67(4):783-813. PubMed ID: 15893553
[TBL] [Abstract][Full Text] [Related]
13. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
14. Drug-resistant human immunodefiency virus.
Kozal MJ
Clin Microbiol Infect; 2009 Jan; 15 Suppl 1():69-73. PubMed ID: 19220361
[TBL] [Abstract][Full Text] [Related]
15. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
[TBL] [Abstract][Full Text] [Related]
16. Current management challenges in HIV: antiretroviral resistance.
Kuritzkes DR; Boyle BA; Gallant JE; Squires KE; Zolopa A
AIDS Read; 2003 Mar; 13(3):133-5, 138-42. PubMed ID: 12728868
[TBL] [Abstract][Full Text] [Related]
17. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
[TBL] [Abstract][Full Text] [Related]
18. New drugs for old.
Winston A; Stebbing J
J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
[TBL] [Abstract][Full Text] [Related]
19. Developments in HIV treatments: strategies for success.
Piliero P
AIDS Read; 2004 Dec; 14(12):655-65. PubMed ID: 15619781
[TBL] [Abstract][Full Text] [Related]
20. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
